Europe Scleroderma Therapeutics Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

 Scleroderma Therapeutics Market Size

• The Europe Scleroderma Therapeutics market size was valued at USD 1.44 billion in 2024 and is expected to reach USD 2.80 billion by 2032, at a CAGR of 8.7% during the forecast period
• This growth is driven by increasing awareness about autoimmune disorders, rising incidence of systemic sclerosis, and improved access to targeted therapies across emerging Asian economies.

Scleroderma Therapeutics Market Analysis

• Scleroderma Therapeutics, also known as biotherapy or immunotherapy, uses living organisms or their components to treat diseases. These therapies have shown significant efficacy in managing cancer, autoimmune disorders, and genetic diseases due to their targeted action and reduced systemic side effects
• The demand for Scleroderma Therapeutics is significantly driven by rising incidences of cancer and autoimmune disorders, expanding approvals of biosimilars, and international investments in biotechnology innovation
• Germany is expected to dominate the Europe Scleroderma Therapeutics market due to advanced healthcare infrastructure, a strong clinical research environment, and active national programs targeting rare diseases like systemic sclerosis.
• Ireland is expected to witness the highest CAGR in the Scleroderma Therapeutics market due to its expanding biotechnology sector, clinical trial activity, and government-supported healthcare innovation.
• Immunosuppressants segment is expected to hold the largest share of 42.5%, due to its widespread use in managing skin fibrosis and systemic complications. Expanding use of corticosteroids and methotrexate-based therapies is fueling demand in primary care settings.

Report Scope and Scleroderma Therapeutics Market Segmentation 

Scleroderma Therapeutics Market Trends

“Integration of Real-World Evidence in Drug Evaluation”

The use of real-world evidence (RWE) is increasingly influencing clinical and regulatory decisions in the Europe Scleroderma Therapeutics market. Real-world data, derived from electronic health records, observational studies, and patient registries, provides critical insights into long-term treatment outcomes and safety profiles outside the controlled environment of clinical trials. Regulatory agencies in countries like Japan and South Korea are actively promoting the integration of patient-reported outcomes and RWE into therapeutic assessments to accelerate drug approval timelines, especially for rare and autoimmune conditions. These initiatives are enabling more accurate benefit-risk evaluations and paving the way for conditional approvals of novel biologics for scleroderma treatment.

Scleroderma Therapeutics Market Dynamics

Driver

“Growing Prevalence of Systemic Sclerosis and Early Diagnosis”

• Europe is witnessing a growing burden of systemic sclerosis, driven by genetic factors, environmental triggers, and improved clinical surveillance.
• Countries like Germany, France, and the United Kingdom are leading early screening initiatives to combat diagnostic delays.
• Early diagnosis programs backed by European rare disease networks are improving access to therapy before irreversible organ damage occurs.

For instance,
In 2024, the United Kingdom’s National Health Service (NHS) introduced a rare disease framework emphasizing early detection and management of systemic autoimmune diseases, including systemic sclerosis.

Opportunity

“Emergence of Biologics for Scleroderma Lung Complications”

• Lung complications such as Interstitial Lung Disease (ILD) and Pulmonary Arterial Hypertension (PAH) are major causes of morbidity.
• Biologics like nintedanib and tocilizumab are being integrated into national treatment guidelines across Germany, Italy, and Spain.

For instance,
In November 2024, Boehringer Ingelheim expanded its clinical trials on nintedanib across major European countries to generate real-world data supporting faster reimbursement approvals.

Restraint/Challenge

“Limited Awareness and High Cost of Advanced Therapies”

• Awareness and affordability remain challenges in parts of Eastern Europe and rural regions of major countries.
• High out-of-pocket expenses and inconsistent insurance coverage for biologics are limiting therapy adoption.

For instance,
In 2023, a study conducted across Eastern Europe (published in The Lancet Rheumatology) found significant disparities in early diagnosis rates and access to advanced therapies compared to Western European countries.

Scleroderma Therapeutics Market Scope

The market is segmented on the basis application, product type, technology, magnification type, end user, and distribution channel.

In 2025, the Immunosuppressants segment is projected to dominate the market with the largest share in drug class segment

In 2025, the Immunosuppressants segment is expected to hold the largest share of 42.5%, due to its widespread use in managing skin fibrosis and systemic complications. Expanding use of corticosteroids and methotrexate-based therapies is fueling demand in primary care settings.

The Systemic Scleroderma segment is expected to account for the largest share during the forecast period in disease type segment

In 2025, the Systemic Scleroderma segment is anticipated to capture a 63.4% share, driven by growing diagnosis of internal organ involvement and increased availability of systemic treatment options.

Scleroderma Therapeutics Market Regional Analysis

“Germany Holds the Largest Share in the Scleroderma Therapeutics Market”

• Germany is expected to dominate due to robust healthcare infrastructure, high clinical trial activity, and availability of advanced biologic therapies.
• Additionally, strong public health programs and insurance systems are boosting early diagnosis and patient access.

“Ireland is Projected to Register the Highest CAGR in the Scleroderma Therapeutics Market”

• Ireland is emerging rapidly due to strong academic-research partnerships, expansion of the biotechnology sector, and national support for rare disease management.
• Increased government investments are driving clinical innovation and faster patient enrollment into specialty therapies.

Scleroderma Therapeutics Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Europe presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

• Boehringer Ingelheim International GmbH (Germany)
• Pfizer Inc. (U.S.)
• Johnson & Johnson Services, Inc. (U.S.)
• Sanofi S.A. (France)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Bayer AG (Germany)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Gilead Sciences, Inc. (U.S.)
• Mitsubishi Tanabe Pharma Corporation (Japan)
• Actelion Pharmaceuticals Ltd (Switzerland)

Latest Developments in Europe Scleroderma Therapeutics Market

• In February 2025, Mitsubishi Tanabe Pharma launched a new topical therapy for localized scleroderma in Europe.
• In January 2025, Roche expanded its Actemra (tocilizumab) scleroderma study to multiple European clinical sites.
• In October 2024, a multicenter trial evaluating sildenafil for digital ulcers in systemic sclerosis was initiated in Germany and Spain.
• In March 2025, Pfizer Inc. collaborated with European Scleroderma Trials and Research group (EUSTAR) to launch a real-world evidence study evaluating immunosuppressant use in systemic sclerosis.
• In April 2025, Roche initiated a Phase II trial across Germany, France, and Italy for a novel antifibrotic monoclonal antibody targeting scleroderma-associated lung fibrosis. 

SKU-34457